GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Shiller PE Ratio

Glaukos (Glaukos) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Shiller PE Ratio Historical Data

The historical data trend for Glaukos's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Shiller PE Ratio Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Glaukos's Shiller PE Ratio

For the Medical Devices subindustry, Glaukos's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Shiller PE Ratio falls into.



Glaukos Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Glaukos's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Glaukos's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.82/131.7762*131.7762
=-0.820

Current CPI (Mar. 2024) = 131.7762.

Glaukos Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.083 100.560 -0.109
201409 -0.060 100.428 -0.079
201412 -0.185 99.070 -0.246
201503 -0.033 99.621 -0.044
201506 -10.960 100.684 -14.345
201509 -0.070 100.392 -0.092
201512 -0.070 99.792 -0.092
201603 0.030 100.470 0.039
201606 0.060 101.688 0.078
201609 0.030 101.861 0.039
201612 0.004 101.863 0.005
201703 0.020 102.862 0.026
201706 -0.100 103.349 -0.128
201709 0.040 104.136 0.051
201712 0.030 104.011 0.038
201803 -0.080 105.290 -0.100
201806 -0.150 106.317 -0.186
201809 -0.190 106.507 -0.235
201812 0.040 105.998 0.050
201903 -0.040 107.251 -0.049
201906 -0.170 108.070 -0.207
201909 -0.370 108.329 -0.450
201912 0.840 108.420 1.021
202003 -1.240 108.902 -1.500
202006 -0.900 108.767 -1.090
202009 -0.350 109.815 -0.420
202012 -0.240 109.897 -0.288
202103 -0.360 111.754 -0.424
202106 -0.380 114.631 -0.437
202109 0.130 115.734 0.148
202112 -0.470 117.630 -0.527
202203 0.110 121.301 0.119
202206 -0.960 125.017 -1.012
202209 -0.580 125.227 -0.610
202212 -0.660 125.222 -0.695
202303 -0.720 127.348 -0.745
202306 -0.680 128.729 -0.696
202309 -0.630 129.860 -0.639
202312 -0.750 129.419 -0.764
202403 -0.820 131.776 -0.820

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (NYSE:GKOS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Glaukos Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022